Daily low-dose cisplatin-based concurrent chemoradiotherapy in patients with uterine cervical cancer with emphasis on elderly patients a phase 2 trial

International Journal of Gynecological Cancer

Volumn 23, Issue 8, 2013, Pages 1453-1458

  Mitsuhashi, Akira ^a   Uno, Takashi ^a   Usui, Hirokazu ^a   Nishikimi, Kyoko ^a   Yamamoto, Noriko ^a   Watanabe, Miho ^a   Tate, Shinichi ^a   Hirashiki, Koichiro ^a   Kato, Kazuyoshi ^a   Yamazawa, Koji ^a   Shozu, Makio ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Cervical cancer; Concurrent chemoradiation; Daily low dose cisplatin; Elderly patient

Indexed keywords

CISPLATIN; CREATININE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; CHEMORADIOTHERAPY; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DIARRHEA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GERIATRIC PATIENT; HERPES ZOSTER; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM HEMORRHAGE; SIDE EFFECT; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VOMITING; WEIGHT REDUCTION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA; CHEMORADIOTHERAPY; CISPLATIN; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84888244190     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182559bda     Document Type: Article

References (19)

1. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340: 1137-1143.
2. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-1161.
3. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144-1153.
4. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339-1348.
5. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781-786.
6. Kunos C, Tian C, Waggoner S, et al. Retrospective analysis of concomitant cisplatin during radiation in patients aged 55 years or older for treatment of advanced cervical cancer: a gynecologic oncology group study. Int J Gynecol Cancer. 2009;19:1258-1263.
7. Goodheart M, Jacobson G, Smith BJ, et al. Chemoradiation for invasive cervical cancer in elderly patients: outcomes and morbidity. Int J Gynecol Cancer. 2008;18:95-103.
8. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effect of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 1992;326:524-530.
9. Pradier O, Lederer K, Weiss E, et al. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter. J Cancer Res Clin Oncol. 2005;131:261-269.
10. Hoebers FJP, Heemsbergen W, Balm AJM, et al. Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma. Radiother Oncol. 2007;85:42-47.
11. Rakovitch E, Tsao M, Ung Y, et al. Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2004;58:196-203.
12. Mitsuhashi A, Uno T, Tanaka N, et al. Phase I study of daily cisplatin and concurrent radiotherapy in patients with cervical carcinoma. Gynecol Oncol. 2005;96:194-197.
13. Kato S, Ohno T, Thephamongkhol K, et al. Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia. Int J Radiat Oncol Biol Phys. 2010;77:751-757.
14. Nugent EK, Case AS, Hoff JT, et al. Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol. 2010;116:438-441.
15. Grigsby PW, Perez CA, Kuske RR, et al. Adenocarcinoma of the uterine cervix: lack of evidence for a poor prognosis. Radiother Oncol. 1988;12:289-296.
16. Hopkins MP, Schmidt RW, Roberts JA, et al. Gland cell carcinoma (adenocarcinoma) of the cervix. Obstet Gynecol. 1988;72:789-795.
17. Eifel PJ, Morris M, Oswald MJ, et al. Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer. 1990;65:2507-2514.
18. Lee JS, Sheets EE, Wenham RM, et al. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol. 2002;84:115-119.
19. Baalbergen A, Ewing-Graham PC, Hop WC, et al. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol. 2004;92:262-267.